A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection

随机对照试验 抗体 医学 内科学 免疫学
作者
Katharina A. Mayer,Eva Schrezenmeier,Matthias Diebold,Philip F Halloran,Martina Schatzl,Sabine Schranz,Susanne Haindl,Silke Kasbohm,Alexander Kainz,Farsad Eskandary,Konstantin Doberer,Uptal D. Patel,Jaideep S. Dudani,Heinz Regele,Nicolas Kozakowski,Johannes Kläger,Rainer Boxhammer,Kerstin Amann,Elisabeth Puchhammer-Stöckl,Hannes Vietzen
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:391 (2): 122-132 被引量:149
标识
DOI:10.1056/nejmoa2400763
摘要

BACKGROUND: Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option. METHODS: In this phase 2, double-blind, randomized, placebo-controlled trial, we assigned patients with antibody-mediated rejection that had occurred at least 180 days after transplantation to receive nine infusions of the CD38 monoclonal antibody felzartamab (at a dose of 16 mg per kilogram of body weight) or placebo for 6 months, followed by a 6-month observation period. The primary outcome was the safety and side-effect profile of felzartamab. Key secondary outcomes were renal-biopsy results at 24 and 52 weeks, donor-specific antibody levels, peripheral NK-cell counts, and donor-derived cell-free DNA levels. RESULTS: A total of 22 patients underwent randomization (11 to receive felzartamab and 11 to receive placebo). The median time from transplantation until trial inclusion was 9 years. Mild or moderate infusion reactions occurred in 8 patients in the felzartamab group. Serious adverse events occurred in 1 patient in the felzartamab group and in 4 patients in the placebo group; graft loss occurred in 1 patient in the placebo group. At week 24, resolution of morphologic antibody-mediated rejection was more frequent with felzartamab (in 9 of 11 patients [82%]) than with placebo (in 2 of 10 patients [20%]), for a difference of 62 percentage points (95% confidence interval [CI], 19 to 100) and a risk ratio of 0.23 (95% confidence interval [CI], 0.06 to 0.83). The median microvascular inflammation score was lower in the felzartamab group than in the placebo group (0 vs. 2.5), for a mean difference of -1.95 (95% CI, -2.97 to -0.92). Also lower was a molecular score reflecting the probability of antibody-mediated rejection (0.17 vs. 0.77) and the level of donor-derived cell-free DNA (0.31% vs. 0.82%). At week 52, the recurrence of antibody-mediated rejection was reported in 3 of 9 patients who had a response to felzartamab, with an increase in molecular activity and biomarker levels toward baseline levels. CONCLUSIONS: Felzartamab had acceptable safety and side-effect profiles in patients with antibody-mediated rejection. (Funded by MorphoSys and Human Immunology Biosciences; ClinicalTrials.gov number, NCT05021484; and EUDRACT number, 2021-000545-40.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
etheral完成签到 ,获得积分10
刚刚
鱼梓发布了新的文献求助10
刚刚
刚刚
1秒前
情怀的应助被Jacky采纳,获得10
1秒前
小燕尾条发布了新的文献求助10
1秒前
hjhhjh完成签到,获得积分10
2秒前
2秒前
2秒前
3秒前
风有约完成签到 ,获得积分10
4秒前
5秒前
踏实凡桃发布了新的文献求助10
5秒前
共享精神的应助被开心德地采纳,获得10
6秒前
打打的应助被整点可乐采纳,获得10
6秒前
6秒前
6秒前
7秒前
8秒前
CipherSage的应助被ke采纳,获得10
8秒前
19完成签到,获得积分10
9秒前
interguy发布了新的文献求助10
9秒前
11秒前
强强完成签到,获得积分10
12秒前
四十发布了新的文献求助10
12秒前
13秒前
14秒前
14秒前
15秒前
踏实凡桃完成签到,获得积分20
15秒前
贾贡献的应助被Dream采纳,获得10
18秒前
18秒前
18秒前
小马甲的应助被开心德地采纳,获得10
19秒前
洁净宝莹发布了新的文献求助10
19秒前
顺利的西瓜完成签到,获得积分10
20秒前
20秒前
求助文献发布了新的文献求助10
20秒前
yanczc发布了新的文献求助10
20秒前
BeBrave1028完成签到,获得积分10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188654
求助须知:如何正确求助?哪些是违规求助? 9576372
关于积分的说明 21847161
捐赠科研通 7786741
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360